The DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index.
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Open accessAbstract
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
RetractedZhang, D., Qiu, X., Li, J., Zheng, S., Li, L., & Zhao, H. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1556064 · Cited by 72
RetractedBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Research works printed but not linked: 1
- Haraldsdottir, 2014, Colorectal cancer—Review, Laeknabladid, 100, 75
Cited by
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Halder, S., Basu, S., Lall, S. P., Ganti, A. K., Batra, S. K., & Seshacharyulu, P. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2218613 · Cited by 133
“AKT/mTOR signaling that supports tumor cell survival, growth, and invasion [8].”
BackgroundCasado, M. E., Collado‐Perez, R., Frago, L. M., & Barrios, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021422 · Cited by 134
“Abnormal activation of this molecule due to changes in the levels of specific interleukins and growth factors is associated with the appearance of cancer [50].”
BackgroundThe Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway
Zoi, V., Kyritsis, A. P., Galani, V., Lazari, D. M., Sioka, C., Voulgaris, S., & Alexiou, G. Α. (2024) · Cancers · doi:10.3390/cancers16081554 · Cited by 119
“…inactivation of the tumor suppressor gene PTEN, and the overexpression of growth factors—such as vascular endothelial growth factor-A (VEGF-A), platelet-derived growth factor (PDGF), or epidermal growth factor (EGF)—are primarily responsible for the dysregulation of the PI3K/Akt pathway [8,9].”
BackgroundZhou, Y., Zhang, W., Wang, B., Wang, P., Li, D., Cao, T., Zhang, D., Han, H., Bai, M., Wang, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008054 · Cited by 107
“As a clinically applicable drug, decitabine shows great potential for promoting pyroptosis in tumors with low endogenous GSDME expression on IR700DX- 6T-PDT treatment.”
BackgroundFerraguti, G., Terracina, S. A., Petrella, C., Greco, A., Minni, A., Lucarelli, M., Agostinelli, E., Ralli, M., VINCENTIIS, M. D., Raponi, G., et al. (2022) · Antioxidants · doi:10.3390/antiox11010145 · Cited by 106
Metadata
- Authors
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M.
- Affiliations
- Department of Family Medicine and Clinical Base, ‘‘Dr. Carol Davila’ Central Military Emergency University Hospital, 051075 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Miricescu, Daniela
- Greabu, Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-23
- Volume
- 22
- Issue
- 19
- Pages
- 10260
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508474
- OpenAlex
- W3200117713
- Cited by
- 402
- References
- 206
- Citations by year
- 2026: 69 · 2025: 134 · 2024: 103 · 2023: 68 · 2022: 26 · 2021: 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, growth factors, PI3K/AKT/mTOR pathway, MAPK signaling, tumor microenvironment, EGFR, IGF-1 receptor, VEGF-A, growth factor inhibitors, colorectal cancer risk factors, colorectal cancer pathogenesis, cell proliferation and invasion
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? https://app.cochat.ai/papers/10.3390/ijms221910260
- The paper
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021). Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now? International Journal of Molecular Sciences. https://doi.org/10.3390/ijms221910260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

